ARAPL Q1 FY27: consolidated loss widens to ₹4.80 Cr, revenue plunges 78% QoQ

Affordable Robotic & Automation's consolidated Q1 FY27 (quarter ended June 30, 2026) results show revenue collapsing to ₹11.03 Cr, down 41% year-on-year from ₹18.77 Cr and down 78% sequentially from ₹50.93 Cr in Q4 FY26. The consolidated net loss widened to ₹4.80 Cr, deeper than the ₹3.69 Cr loss reported in the year-ago quarter (loss up ~30% YoY) and a sharp reversal from the ₹4.78 Cr profit booked in Q4 FY26. Standalone tells the same story — a ₹4.80 Cr loss (EPS -₹4.05), materially identical to consolidated, confirming the subsidiaries (ARAPL RaaS, Masterji.AI) contributed little incremental scale this quarter. No exceptional items were recorded in either period, so the swing is entirely operating: total expenses of ₹15.89 Cr consolidated outran total income of ₹11.09 Cr, pushing both operating and net margins into negative territory versus the 9.1% NPM/16.07% OPM posted just one quarter earlier. Management's own release characterizes this quarter's performance as negative, consistent with the print, though its outlook commentary stays neutral. That directly contradicts the confident, growth-oriented tone from the Q4 FY26 concall, where management flagged $100k/month in incoming RaaS revenue, a ₹60 Cr outright-sales pipeline, and 'radical growth' expectations tied to a new export product slated for Nov/Dec 2026 — none of that shows up in this quarter's numbers, so the print reads as a clear miss against that guidance. We found no formal analyst/street estimates for this micro-cap, so vsStreet is unknown. The revenue trough also sits oddly against a reported ₹127.16 Cr order book as of end-May 2026, suggesting the shortfall may be a project execution/revenue-recognition timing issue rather than a fresh demand problem — something Q2 delivery will need to confirm. Separately, the board approved a ₹21 Cr warrant issue to the promoter (Jul 17–23, 2026), partly converted already and taking paid-up capital to ₹11.85 Cr from ₹11.25 Cr — a capital infusion landing right alongside this weak print that warrants tracking for dilution and use of proceeds.